Caspian Therapeutics

Private

Clinical-stage biopharmaceutical company spun out from Kura Oncology to develop small-molecule menin inhibitors as potentially disease-modifying therapies for diabetes and cardiometabolic diseases.

Company Info

Sector:Small Molecule Pharma

Headquarters:San Diego, California, United States

Founded:2026

Website:kuraoncology.com/

Funding Round:Series A

Total Funding:$50M

Funding & Investor Relations

Notable Investors

BVF Partners
T1D Fund
Invus
Montanova
Eli Lilly
Kura Oncology

Upcoming Milestones & Key Dates

2026-09-09

Corporate

Launch announcement with $50M financing

2027

Regulatory

Expected IND submission for KO-7246

Clinical Development Pipeline

KO-7246

Target: Menin

Type 2 Diabetes

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Troy Wilson

Chairman (also CEO of Kura Oncology)

Careers & Job Openings

See all open roles

Various

San Diego, CA

Apply Now →